This inventor holds 6 USPTO granted patents. Top assignees: The Salk Institute, University of California. Active years: 1984-1997.
Company Filing History:
6 out of 593 
1 out of 15,988 
Years Active: 1984-1997
Title: Ian S Trowbridge: Innovator in Monoclonal Antibody Research
Introduction
Ian S Trowbridge is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies for cancer treatment. With a total of 6 patents, Trowbridge's work has the potential to impact therapeutic strategies for tumor cell proliferation.
Latest Patents
Trowbridge's latest patents focus on enhancing the inhibition of tumor cell proliferation through innovative combinations of monoclonal antibodies. One of his notable inventions discloses methods for employing these antibodies, which are capable of binding to the human transferrin receptor glycoprotein. The combinations he developed exhibit a substantially greater inhibition of cell growth than either antibody used individually when administered in comparable amounts. This approach is particularly effective when at least one member of the combination is highly effective in inhibiting cell growth, while another may be substantially ineffective. The selection of these combinations is based on in vitro screening tests using CCRF-CEM cells that express the human transferrin receptor.
Another significant patent involves the production of monoclonal antibodies that specifically bind to epitopes found in the cytoplasmic domain of the transferrin receptor. These antibodies are instrumental in isolating sequences in samples that contain the TR cytoplasmic domain, further advancing the understanding of this critical receptor.
Career Highlights
Throughout his career, Ian S Trowbridge has worked with esteemed institutions such as the Salk Institute and the University of California. His research has been pivotal in the advancement of therapeutic techniques aimed at combating cancer through targeted antibody therapies.
Collaborations
Trowbridge has collaborated with notable colleagues, including Suhaila N White and Clare M Isacke. These partnerships have fostered a collaborative environment that enhances the innovation and application of his research findings.
Conclusion
Ian S Trowbridge stands out as a key figure in the field of monoclonal antibody research, with a focus on innovative solutions for cancer treatment. His contributions through patents and collaborations continue to pave the way for advancements in biomedical science.